BRAF and keratoacanthoma: Certain drugs modulate risk: BRAF inhibitors can trigger eruptive keratoacanthomas/cSCC via paradoxical MAPK activation in RAS-mutant keratinocytes, an effect mitigated by MEK co-inhibition, while long-term voriconazole and vismodegib have also been linked to increased cSCC incidence [43,44].